NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

If you're looking for cheap growth stocks to buy, three you'll want to consider today are Novo Nordisk ( NVO 3.76%), Carnival ...

Novo Nordisk A/S (NYSE:NVO – Get Free Report) shares gapped up before the market opened on Wednesday after the company announced better than expected quarterly earnings. The stock had previously ...

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors acquired 56,398 call options on the company. This represents an ...

Novo Nordisk reported strong sales growth for its Wegovy and Ozempic drugs, while its 2025 guidance topped expectations. Shares in Novo, one of Europe's largest listed companies, rallied in the U.S.

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...

In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Shares of Novo Nordisk (NYSE: NVO) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...